126 related articles for article (PubMed ID: 37163820)
21. Corrigendum to "Zinc supplement reduces allergic responses through modulating the p38 MAPK pathway activation in an allergic rhinitis mouse model" [J. Trace Elem. Med. Biol. 75 (2023) 127094].
Shi Q; Shen X; Long C; Mi Z; Li Y; Ma R
J Trace Elem Med Biol; 2023 May; 77():127150. PubMed ID: 36921372
[No Abstract] [Full Text] [Related]
22. Retraction notice to "A novel concept to derive iodine status of human populations from frequency distribution properties of a hair iodine concentration" [J. Trace. Elem. Med. Biol. 28 (2014) 205-211].
Prejac J; Višnjević V; Drmić S; Skalny AA; Imica NM; Momčilović B
J Trace Elem Med Biol; 2020 Jan; 57():126393. PubMed ID: 31548111
[No Abstract] [Full Text] [Related]
23. Corrigendum to "Synthesis and characterization of new 1-hydroxy-2-pyridinethione derivatives: Their lead complexes and efficacy in the treatment of acute lead poisoning in rats" [J. Trace Elem. Med. Biol. 44 (December 2017) 209-217].
Al Khabbas MH; Ata SA; Abu-Dari KI; Tutunji MF; Mubarak MS
J Trace Elem Med Biol; 2019 Sep; 55():214. PubMed ID: 29426640
[No Abstract] [Full Text] [Related]
24. Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
McDonald AC; Gernand J; Geyer NR; Wu H; Yang Y; Wang M
Cancer; 2022 May; 128(9):1832-1839. PubMed ID: 35195279
[TBL] [Abstract][Full Text] [Related]
25. Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.
Santambrogio L; Rammensee HG
Immunogenetics; 2019 Mar; 71(3):203-216. PubMed ID: 30343358
[TBL] [Abstract][Full Text] [Related]
26. Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
Rocco B; Sighinolfi MC
Eur Urol; 2024 Feb; 85(2):e40. PubMed ID: 37684177
[No Abstract] [Full Text] [Related]
27. Corrigendum to "Salivary levels of nickel, chromium, iron, and copper in patients treated with metal or esthetic fixed orthodontic appliances: A retrospective cohort study" [J. Trace Elem. Med. Biol. 40 (2017) 67-71].
Lages RB; Bridi EC; Pérez CA; Basting RT
J Trace Elem Med Biol; 2018 Jan; 45():189-190. PubMed ID: 28801010
[No Abstract] [Full Text] [Related]
28. Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
[TBL] [Abstract][Full Text] [Related]
29. Corrigendum to "Confirmation of the systematic presence of tin particles in fallopian tubes or uterine horns of Essure implant explanted patients: A study of 18 cases with the same pathological process" [J. Trace Elem. Med. Biol. 69 (2022) 126891].
Catinon M; Roux E; Auroux A; Trunfio-Sfarghiu AM; Lauro-Colleaux C; Watkin E; Sournies G; Vincent M
J Trace Elem Med Biol; 2022 Jul; 72():126970. PubMed ID: 35567911
[No Abstract] [Full Text] [Related]
30. Does arsenic exposure increase the risk for prostate cancer?
Yang CY; Chang CC; Chiu HF
J Toxicol Environ Health A; 2008; 71(23):1559-63. PubMed ID: 18923998
[TBL] [Abstract][Full Text] [Related]
31. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
Morote J
Eur Urol Oncol; 2023 Apr; 6(2):234. PubMed ID: 36894492
[No Abstract] [Full Text] [Related]
32. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
Lenfant L; Mozer P; Seisen T
Eur Urol Oncol; 2023 Apr; 6(2):235. PubMed ID: 36707321
[No Abstract] [Full Text] [Related]
33. In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).
Pickles T; Williams SG
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):318-9; author reply 319. PubMed ID: 17189080
[No Abstract] [Full Text] [Related]
34. Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142.
Di Lorenzo G; Buonerba C
Eur Urol; 2022 Jul; 82(1):e17. PubMed ID: 35393160
[No Abstract] [Full Text] [Related]
35. Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
Leppert JT; Brooks JD
Eur Urol; 2018 Nov; 74(5):e110-e111. PubMed ID: 30017399
[No Abstract] [Full Text] [Related]
36. Trace elements and cancer risk: a review of the epidemiologic evidence.
Navarro Silvera SA; Rohan TE
Cancer Causes Control; 2007 Feb; 18(1):7-27. PubMed ID: 17186419
[TBL] [Abstract][Full Text] [Related]
37. Re.: "Zinc distribution and expression pattern of ZnT3 in mouse brain" by Shen et al., Biol Trace Elem Res 119:166-174 (2007).
Shen H
Biol Trace Elem Res; 2008 Mar; 121(3):288. PubMed ID: 17985085
[No Abstract] [Full Text] [Related]
38. Arsenic and prostate cancer.
Harv Mens Health Watch; 2009 Aug; 14(1):5, 7. PubMed ID: 19757530
[No Abstract] [Full Text] [Related]
39. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
Mahal BA; D'Amico AV; Nguyen PL
Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
[No Abstract] [Full Text] [Related]
40. RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101.
Wallis CJD; Klaassen Z
Eur J Cancer; 2018 May; 94():216-217. PubMed ID: 29573942
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
